Project Grant R01AI203258
Award Date 8/18/26
Completion Date 7/31/31
Dollars Obligated $795K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pittsburgh, PA 15213, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded the University of Pittsburgh $790,847 on February 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate HIV-1 resistance to lenacapavir, a potent capsid inhibitor, through in vitro and in vivo models. The research will elucidate how HIV-1 acquires resistance to lenacapavir using rationally designed, accelerated in vitro evolution approaches with large-scale mutant libraries and multiplex...
- The National Institute of Allergy and Infectious Diseases awarded Drexel University $624,806 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and characterize nanotrap therapeutic vaccines for HIV treatment. The project, titled "Nanotrap Therapeutic Vaccines for HIV Virion Capture and Infected Cell Targeting" (R01AI203404), will engineer liposomal nanoparticles displaying multivalent CD4 mimetic ligands designed to capture...
- The National Institute of Allergy and Infectious Diseases awarded The Wistar Institute of Anatomy and Biology $707,928 on July 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research on epitope-engineered hematopoietic stem cells to enable CAR-T cell-mediated CD4 depletion as an HIV cure strategy. The project integrates genome editing with targeted cellular immunotherapy to establish an HIV-refractory immune system while eliminating persistent HIV-infected...
- The National Institute of Allergy and Infectious Diseases awarded the University of Pittsburgh $814,507 on September 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize HIV-1 reservoir dynamics and immune responses in individuals who acquire HIV-1 while on pre-exposure prophylaxis. The research compares two populations: 20 individuals who acquired HIV-1 while on PrEP (such as long-acting cabotegravir) and 40 individuals who initiated antiretroviral...
- The National Institute of Allergy and Infectious Diseases awarded The Salk Institute for Biological Studies $161,868 on June 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to elucidate the mutational pathways and molecular mechanisms through which drug resistance evolves against latest-generation antiretroviral therapy drugs for HIV. The research combines three complementary approaches. First, the work uses Potts sequence-covariation fitness landscape models...
- The National Institute of Allergy and Infectious Diseases awarded $194,375 to the University of North Carolina at Chapel Hill on May 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop bifunctional molecules targeting HIV latency reversal through BRD4 recruitment to the viral promoter. The research addresses the heterogeneity of the viral reservoir and multiple mechanisms maintaining HIV latency, which single latency reversal agents cannot overcome. The...
- The National Institute of Allergy and Infectious Diseases awarded Scripps Research Institute $276,000 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to evaluate HIV-1 envelope-C3D constructs on nanoparticles for structure, function, and immunogenicity. Scripps will assess ENV-C3D fusion candidates carrying two and three copies of C3D domains per GP160 subunit (with or without Fc domain) in C57BL/6 and alloy mice. The research will measure germinal...
- The National Institute of Allergy and Infectious Diseases awarded San Diego Biomedical Research Institute $992,920 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research on nanoscale imaging of cell surface HIV envelope immune complexes to optimize natural killer cell antibody-dependent cellular cytotoxicity (ADCC) therapeutics. The project integrates nanoscale imaging, machine learning, and in silico protein modeling to characterize the...
- The National Institute of Allergy and Infectious Diseases awarded The Salk Institute for Biological Studies $237,932 on October 24, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct structural and biochemical studies of HIV and mouse mammary tumor virus (MMTV) retroviral integration onto nucleosome-bound target DNA. The recipient will employ nucleosome reconstitution and sequencing strategies, biochemical binding and activity assays, and high-resolution...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded Emory University $909,998 on February 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize antibody-mediated establishment of an SIV reservoir using an art-free approach. The project, designated R01AI198034, runs through January 31, 2031, with place of performance in Atlanta, Georgia. The research employs adeno-associated virus (AAV) vectors to deliver broadly neutralizing...